Skip to content

Pepsinogen-1 Serum Levels in Hyperemesis Gravidarum

Examination of the Maternal Serum Pepsinogen-1 in Patients Diagnosed With Severe Hyperemesis Gravidarum: A Prospective Case-control Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06581796
Enrollment
40
Registered
2024-09-03
Start date
2024-07-01
Completion date
2024-11-21
Last updated
2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperemesis Gravidarum, Pregnant With Complication

Keywords

Pepsinogen, Hyperemesis, Pregnancy

Brief summary

In this study, the investigators planned to investigate maternal serum pepsinogen-1 (MSPG-1) levels in pregnant women with severe hyperemesis gravidarum (HG) and pregnant women without severe HG. HG is the most common cause of hospitalization in the first trimester of pregnancy and represents an economic burden on the healthcare system. Therefore, our aim in this study was to investigate whether there is a statistical difference in MSPG-1 levels between pregnant women with severe HG and pregnant women without severe HG and to determine a cut-off value for MSPG-1 levels for the indication of hospitalization of pregnant women with HG. The study poses no risk to the pregnant woman or the fetus.

Detailed description

The study will enroll pregnant women in the first trimester with maternal age between 21 and 35 years who were diagnosed with hyperemesis gravidarum and had no fetal congenital or chromosomal abnormalities and who were admitted to the perinatology outpatient clinic of Etlik City Hospital. The investigators will include 40 cases with no signs and diagnosis of systemic maternal disease and no chronic drug use as a case group and 40 healthy pregnant women matched for age, gestational week and body mass index as a control group.

Interventions

OTHERpepsinogen-1

association between pepsinogen 1 serum level with hyperemesis gravidarum

Sponsors

Ankara Etlik City Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* A singleton pregnancy * Between 21 and 35 years old * Diagnosis of hyperemesis gravidarum

Exclusion criteria

* Multiple pregnancy * Fetal congenital and chromosomal abnormalities * Chronic drug use, alcohol and smoking * Pregnant women with diabetes or obesity, peptic ulcer or gastritis, liver and/or gallbladder disease (cholangitis or gallstones), thyroid dysfunction, urinary tract infection, celiac disease, cardiovascular or renal disease

Design outcomes

Primary

MeasureTime frameDescription
Pepsinogen-1 serum levelbetween 5 and 14 weeks of pregnancypepsinogen-1 serum level was determined with blood samples taken from pregnant women with hyperemesis gravidarum and control group.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026